{"url":"https://newsforagent.com/news/2026-10-25/frontier-medicines-fmc-376-prosper-data","markdown_url":"https://newsforagent.com/news/2026-10-25/frontier-medicines-fmc-376-prosper-data.md","title":"Frontier Medicines FMC-376 Hits 56% Response Rate","headline":"Frontier Medicines Reports 56% Response Rate for FMC-376 in Resistant Lung Cancer","description":"Frontier Medicines reported a 56% confirmed response rate for FMC-376 in 18 KRAS G12C-mutant NSCLC patients, with 7.5 months median duration of response.","section":"Research & Clinical Trials","published_at":"2026-10-25T08:06:17+00:00","modified_at":"2026-10-25T08:06:17+00:00","author":"News Desk","key_takeaways":["FMC-376 produced a 56% confirmed overall response rate in 18 response-evaluable NSCLC patients treated at 500 mg twice daily.","Median duration of response was 7.5 months, with treatment ongoing for six of the 10 responders.","Frontier Medicines has raised $335.5 million in total, including a $100 million Series C completed in June 2024."],"companies":[{"name":"Frontier Medicines","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000feg/frontier-medicines","website":"https://frontiermeds.com"}],"source":{"publisher":"Business Wire","title":"Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026","url":"https://www.businesswire.com/news/home/20261024166774/en/"},"other_sources":[],"tags":["Research & Clinical Trials","Frontier Medicines"],"body_markdown":"Frontier Medicines reported a 56% confirmed overall response rate for FMC-376 in 18 response-evaluable patients with KRAS G12C-mutant non-small cell lung cancer, with a median duration of response of 7.5 months. The company presented the Phase 1/2 PROSPER trial data at the European Society for Medical Oncology Congress 2026 in Madrid, [Business Wire](https://www.businesswire.com/news/home/20261024166774/en/) reported on October 25, 2026.\n\n## How FMC-376 Performed in the PROSPER Trial\n\n[Frontier Medicines](https://akta.pro/company-profiles/0000feg/frontier-medicines) is a clinical-stage precision medicines company developing covalent small-molecule drugs against previously undruggable cancer targets through its chemoproteomics- and AI-powered Frontier Platform. FMC-376 is an equipotent ON+OFF KRAS G12C inhibitor designed to address resistance and tolerability limits of current KRAS G12C inhibitors.\n\nThe efficacy analysis covered 18 NSCLC patients treated at 500 mg twice daily after prior chemotherapy or immunotherapy in the metastatic setting, with response confirmation updated through July 14, 2026. Patients had received a median of three prior lines of therapy, and nine had previously received and failed up to two OFF-state KRAS G12C inhibitors. The confirmed overall response rate was 67% (6/9) in KRAS G12C inhibitor-naïve patients and 44% (4/9) in patients previously treated with an OFF-state KRAS G12C inhibitor. Disease control rate was 89% (16/18), including 100% (9/9) in KRAS G12C inhibitor-naïve patients and 78% (7/9) in KRAS G12C inhibitor-pretreated patients.\n\nNine of the 10 responders had at least one co-alteration associated with clinical resistance to KRAS inhibitors, including KRAS G12C amplifications in four responders. At 500 mg twice daily, one treatment-related hepatic transaminase elevation was reported, which was Grade 2 (3%). No Grade 3 or 4 gastrointestinal toxicities and no discontinuations due to adverse events were reported at that dose or below.\n\n\"These first clinical data for FMC-376 mark an important step for Frontier, demonstrating encouraging responses and durability in a highly G12C-resistant population, as well as a favorable hepatic safety profile that we believe could be particularly important in combination with pembrolizumab in the first-line setting,\" said Chris Varma, Ph.D., co-founder, chairperson and chief executive officer of Frontier Medicines.\n\n## Frontier Medicines Funding and Pipeline Records\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Frontier Medicines has raised $335.5 million in total, including a $100 million Series C completed in June 2024 that combined an $80 million round in February 2024 with a $20 million extension. The same records list four funding rounds on file and a valuation estimate of $500 million to $1 billion. Frontier Medicines is pre-revenue and based in South San Francisco.\n\n## Earlier Frontier Medicines Disclosures\n\nFrontier Medicines said on October 19, 2026, that it would present preliminary clinical data from the Phase 1 portion of the PROSPER trial for FMC-376 at ESMO Congress 2026 in Madrid, Business Wire Blog reported. In August 2026, chief executive Chris Varma told FierceBiotech the biotech was advancing more cancer drugs into the clinic after a February 2025 layoff announcement, with the number of employees let go not disclosed.\n\n## What Comes Next for the PROSPER Study\n\nThe Phase 1/2 PROSPER trial continues, including a dose-escalation cohort testing FMC-376 with pembrolizumab. As of September 16, 2026, three patients had enrolled and received FMC-376 200 mg twice daily plus pembrolizumab, with no Grade 3 or higher gastrointestinal or hepatic transaminase adverse events and no treatment-related discontinuations. The trial also includes a Phase 1b dose-ranging cohort and a first-line NSCLC monotherapy cohort.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}